Literature DB >> 21472473

Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility.

C Messiou1, D J Collins, V A Morgan, N M Desouza.   

Abstract

OBJECTIVES: To establish normal bone marrow values of apparent diffusion coefficient (ADC) over an age range, compare them with metastatic and myelomatous involvement, to establish reproducibility and to optimise b values.
METHODS: The ADCs of bone marrow in 7 volunteers (mean age 29.7 years), 34 volunteers (mean age 63.3 years) and 43 patients with metastatic and myelomatous involvement (mean age 65.5 years) were measured. In 9 volunteers diffusion weighted MRI was repeated within 7 days. b values were derived to optimise contrast between normal and pathological marrow.
RESULTS: The mean ADC of bone marrow in younger volunteers was significantly higher than that of older volunteers. The coefficient of reproducibility was 14.8%. The ADC mean of metastatic and myeloma bone disease was 1054 + / -456 x 10⁻⁶mm²s⁻¹. An ADC threshold of 655 × 10(-6) mm(2)s(-1) separated normal and abnormal marrow with a sensitivity and specificity of 90% and 93% respectively. Contrast between normal and abnormal marrow was optimal at b = 1389 smm(-2).
CONCLUSION: The reproducibility of ADC measurements in bone is equivalent to published data for soft tissue with a high sensitivity and specificity for separating abnormal from age matched normal bone marrow. A b value of around 1,400 smm(-2) is optimal for imaging bone marrow.

Entities:  

Mesh:

Year:  2011        PMID: 21472473     DOI: 10.1007/s00330-011-2116-4

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  22 in total

1.  Vertebral metastases: assessment with apparent diffusion coefficient.

Authors:  Andreas M Herneth; Marcel O Philipp; Jonathan Naude; Martin Funovics; Reinhard R Beichel; Roland Bammer; Herwig Imhof
Journal:  Radiology       Date:  2002-12       Impact factor: 11.105

2.  Usefulness of diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas.

Authors:  T Sugahara; Y Korogi; M Kochi; I Ikushima; Y Shigematu; T Hirai; T Okuda; L Liang; Y Ge; Y Komohara; Y Ushio; M Takahashi
Journal:  J Magn Reson Imaging       Date:  1999-01       Impact factor: 4.813

3.  Quantitative and diffusion MR imaging as a new method to assess osteoporosis.

Authors:  H G Hatipoglu; A Selvi; D Ciliz; E Yuksel
Journal:  AJNR Am J Neuroradiol       Date:  2007-09-28       Impact factor: 3.825

Review 4.  Diffusion-weighted magnetic resonance imaging and its application to cancer.

Authors:  Elizabeth M Charles-Edwards; Nandita M deSouza
Journal:  Cancer Imaging       Date:  2006-09-13       Impact factor: 3.909

5.  Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging.

Authors:  K M Gauvain; R C McKinstry; P Mukherjee; A Perry; J J Neil; B A Kaufman; R J Hayashi
Journal:  AJR Am J Roentgenol       Date:  2001-08       Impact factor: 3.959

6.  Vertebral bone mineral density, marrow perfusion, and fat content in healthy men and men with osteoporosis: dynamic contrast-enhanced MR imaging and MR spectroscopy.

Authors:  James F Griffith; David K W Yeung; Gregory E Antonio; Francis K H Lee; Athena W L Hong; Samuel Y S Wong; Edith M C Lau; Ping Chung Leung
Journal:  Radiology       Date:  2005-07-29       Impact factor: 11.105

Review 7.  Diffusion-weighted MRI in the body: applications and challenges in oncology.

Authors:  Dow-Mu Koh; David J Collins
Journal:  AJR Am J Roentgenol       Date:  2007-06       Impact factor: 3.959

8.  An imaging biomarker of early treatment response in prostate cancer that has metastasized to the bone.

Authors:  Kuei C Lee; Sudha Sud; Charles R Meyer; Bradford A Moffat; Thomas L Chenevert; Alnawaz Rehemtulla; Kenneth J Pienta; Brian D Ross
Journal:  Cancer Res       Date:  2007-04-15       Impact factor: 12.701

9.  Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial.

Authors:  Dow-Mu Koh; Matthew Blackledge; David J Collins; Anwar R Padhani; Toni Wallace; Benjamin Wilton; N Jane Taylor; J James Stirling; Rajesh Sinha; Pat Walicke; Martin O Leach; Ian Judson; Paul Nathan
Journal:  Eur Radiol       Date:  2009-06-23       Impact factor: 5.315

10.  A feasibility study evaluating the functional diffusion map as a predictive imaging biomarker for detection of treatment response in a patient with metastatic prostate cancer to the bone.

Authors:  Kuei C Lee; Deborah A Bradley; Maha Hussain; Charles R Meyer; Thomas L Chenevert; Jon A Jacobson; Timothy D Johnson; Craig J Galban; Alnawaz Rehemtulla; Kenneth J Pienta; Brian D Ross
Journal:  Neoplasia       Date:  2007-12       Impact factor: 5.715

View more
  44 in total

1.  Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.

Authors:  Nicolas F Michoux; Jakub W Ceranka; Jef Vandemeulebroucke; Frank Peeters; Pierre Lu; Julie Absil; Perrine Triqueneaux; Yan Liu; Laurence Collette; Inneke Willekens; Carola Brussaard; Olivier Debeir; Stephan Hahn; Hubert Raeymaekers; Johan de Mey; Thierry Metens; Frédéric E Lecouvet
Journal:  Eur Radiol       Date:  2021-01-06       Impact factor: 5.315

2.  Is there a role for diffusion-weighted MRI (DWI) in the diagnosis of central cartilage tumors?

Authors:  H Douis; L Jeys; R Grimer; S Vaiyapuri; A M Davies
Journal:  Skeletal Radiol       Date:  2015-03-07       Impact factor: 2.199

Review 3.  Myeloma Response Assessment and Diagnosis System (MY-RADS): strategies for practice implementation.

Authors:  Michael E Mulligan
Journal:  Skeletal Radiol       Date:  2021-03-06       Impact factor: 2.199

4.  Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences.

Authors:  Ahmed Larbi; Patrick Omoumi; Vassiliki Pasoglou; Nicolas Michoux; Perrine Triqueneaux; Bertrand Tombal; Catherine Cyteval; Frédéric E Lecouvet
Journal:  Eur Radiol       Date:  2018-11-09       Impact factor: 5.315

Review 5.  Whole-body MRI, dynamic contrast-enhanced MRI, and diffusion-weighted imaging for the staging of multiple myeloma.

Authors:  Julie C Dutoit; Koenraad L Verstraete
Journal:  Skeletal Radiol       Date:  2017-03-13       Impact factor: 2.199

6.  Assessing response in bone metastases in prostate cancer with diffusion weighted MRI.

Authors:  C Messiou; D J Collins; S Giles; J S de Bono; D Bianchini; N M de Souza
Journal:  Eur Radiol       Date:  2011-06-28       Impact factor: 5.315

Review 7.  Functional and molecular MRI of the bone marrow in multiple myeloma.

Authors:  Vassilis Koutoulidis; Nickolas Papanikolaou; Lia A Moulopoulos
Journal:  Br J Radiol       Date:  2018-02-13       Impact factor: 3.039

8.  The diagnostic value of SE MRI and DWI of the spine in patients with monoclonal gammopathy of undetermined significance, smouldering myeloma and multiple myeloma.

Authors:  Julie C Dutoit; Matthias A Vanderkerken; Joris Anthonissen; Frederick Dochy; Koenraad L Verstraete
Journal:  Eur Radiol       Date:  2014-08-09       Impact factor: 5.315

9.  Diffusion-weighted MR imaging for characterizing musculoskeletal lesions.

Authors:  Ty K Subhawong; Michael A Jacobs; Laura M Fayad
Journal:  Radiographics       Date:  2014 Sep-Oct       Impact factor: 5.333

10.  Assessing response of myeloma bone disease with diffusion-weighted MRI.

Authors:  C Messiou; S Giles; D J Collins; S West; F E Davies; G J Morgan; N M Desouza
Journal:  Br J Radiol       Date:  2012-12       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.